Dynavax Technologies PE Ratio 2010-2022 | DVAX
Current and historical p/e ratio for Dynavax Technologies (DVAX) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Dynavax Technologies PE ratio as of February 03, 2023 is 5.67.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Dynavax Technologies PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-02-03 |
11.69 |
|
5.65 |
| 2022-09-30 |
10.44 |
$2.07 |
5.04 |
| 2022-06-30 |
12.59 |
$1.40 |
8.99 |
| 2022-03-31 |
10.84 |
$0.55 |
19.71 |
| 2021-12-31 |
14.07 |
$0.34 |
41.38 |
| 2021-09-30 |
19.21 |
$-0.35 |
0.00 |
| 2021-06-30 |
9.85 |
$-0.26 |
0.00 |
| 2021-03-31 |
9.83 |
$-0.81 |
0.00 |
| 2020-12-31 |
4.45 |
$-1.07 |
0.00 |
| 2020-09-30 |
4.32 |
$-1.37 |
0.00 |
| 2020-06-30 |
8.87 |
$-1.71 |
0.00 |
| 2020-03-31 |
3.53 |
$-1.84 |
0.00 |
| 2019-12-31 |
5.72 |
$-2.21 |
0.00 |
| 2019-09-30 |
3.58 |
$-2.41 |
0.00 |
| 2019-06-30 |
3.99 |
$-2.57 |
0.00 |
| 2019-03-31 |
7.31 |
$-2.54 |
0.00 |
| 2018-12-31 |
9.15 |
$-2.55 |
0.00 |
| 2018-09-30 |
12.40 |
$-2.36 |
0.00 |
| 2018-06-30 |
15.25 |
$-2.09 |
0.00 |
| 2018-03-31 |
19.85 |
$-1.87 |
0.00 |
| 2017-12-31 |
18.70 |
$-1.84 |
0.00 |
| 2017-09-30 |
21.50 |
$-1.95 |
0.00 |
| 2017-06-30 |
9.65 |
$-2.47 |
0.00 |
| 2017-03-31 |
5.95 |
$-2.81 |
0.00 |
| 2016-12-31 |
3.95 |
$-2.91 |
0.00 |
| 2016-09-30 |
10.49 |
$-3.05 |
0.00 |
| 2016-06-30 |
14.58 |
$-2.97 |
0.00 |
| 2016-03-31 |
19.24 |
$-3.02 |
0.00 |
| 2015-12-31 |
24.16 |
$-3.29 |
0.00 |
| 2015-09-30 |
24.54 |
$-3.44 |
0.00 |
| 2015-06-30 |
23.43 |
$-3.72 |
0.00 |
| 2015-03-31 |
22.43 |
$-2.02 |
0.00 |
| 2014-12-31 |
16.86 |
$-1.55 |
0.00 |
| 2014-09-30 |
14.30 |
$-1.60 |
0.00 |
| 2014-06-30 |
16.00 |
$-1.40 |
0.00 |
| 2014-03-31 |
18.08 |
$-3.20 |
0.00 |
| 2013-12-31 |
19.60 |
$-3.80 |
0.00 |
| 2013-09-30 |
11.90 |
$-4.00 |
0.00 |
| 2013-06-30 |
11.00 |
$-4.10 |
0.00 |
| 2013-03-31 |
22.20 |
$-4.10 |
0.00 |
| 2012-12-31 |
28.50 |
$-4.10 |
0.00 |
| 2012-09-30 |
47.60 |
$-3.30 |
0.00 |
| 2012-06-30 |
43.20 |
$-3.50 |
0.00 |
| 2012-03-31 |
50.30 |
$-3.50 |
0.00 |
| 2011-12-31 |
33.20 |
$-4.00 |
0.00 |
| 2011-09-30 |
18.60 |
$-5.10 |
0.00 |
| 2011-06-30 |
27.50 |
$-4.50 |
0.00 |
| 2011-03-31 |
27.60 |
$-7.00 |
0.00 |
| 2010-12-31 |
32.00 |
$-7.10 |
0.00 |
| 2010-09-30 |
18.30 |
$-13.00 |
0.00 |
| 2010-06-30 |
18.60 |
$-14.80 |
0.00 |
| 2010-03-31 |
13.00 |
$-10.40 |
0.00 |
| 2009-12-31 |
14.20 |
$-7.40 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.491B |
$0.439B |
|
Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
|
